Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR) is a leading company in the field of precision oncology. Our mission is to Guard Life via Science.

[Burning Rock @BurningRock2014]

📢Burning Rock Q1 2026 Results

Our compliance transformation pays off.👌

✅Total revenue: US$ 15.6M.
✅In-hospital revenue US$ 7.6M (+3.4% QoQ, 49% share).
✅Pharma revenue US$ 3.3M, 15+ active projects.
✅Expenses US$ 14.1M, down 10%+ YoY & QoQ amid better efficiency.

[Burning Rock @BurningRock2014]

We’re excited to announce that Burning Rock Dx will be attending the 59th European Human Genetics Conference (ESHG 2026)– a key gathering for over 3,000 geneticists, clinicians, and biotech innovators exploring the frontiers of genomic medicine.
📍 Meet us at Booth #430

[Burning Rock @BurningRock2014]

SPIRAL: Multi-omic liquid biopsy for breast cancer diagnosis.

✅100% specificity for benign/malignant lesion differentiation
✅Sensitivity up to 100% at stage IV
✅Validated for non-invasive diagnosis

Learn More：https://t.co/rjvouw0H43

#BreastCancer #MultiOmics

[Burning Rock @BurningRock2014]

CanCatch Custom: Personalized ctDNA #MRD monitoring for high-risk GIST.

✅Sustained MRD+ is an independent risk factor for shorter DFS
✅Detects recurrence earlier than imaging
✅First non-invasive ctDNA surveillance system for #GIST

Learn More: https://t.co/RJvdBAdDaw

[Burning Rock @BurningRock2014]

CanCatch Surf: Preoperative ctDNA risk stratification for early #NSCLC.

✅Cross-stage stratifies stage I LUAD
✅ctDNA+ predicts poor prognosis independently
✅ctDNA+ links to early recurrence
✅2y RFS: 60% (ctDNA+) vs 96% (ctDNA−)
✅Refines pathological risk stratification

[Burning Rock @BurningRock2014]

At #ASCO 2026, Burning Rock CDx presented 3 #liquidbiopsy studies, advancing precision oncology in NSCLC, GIST, and breast cancer.

Our proprietary platforms — CanCatch Surf, CanCatch Custom, SPIRAL — deliver non-invasive, actionable insights across the full cancer care journey.

[Burning Rock @BurningRock2014]

One sample. Multi-omics insight.

At #AACR2026, Burning Rock shared SPIRAL data showing methylation LoD ~1e-4 and 0.54–0.79% for genomic variants, with strong NGS concordance.

Supports scalable multi-omics testing.

#PrecisionOncology

[Burning Rock @BurningRock2014]

One plasma sample. Multi-marker CRC profiling.

At #AACR2026, Burning Rock presented 25-plex ddPCR data detecting KRAS/NRAS/BRAF, MSI, and methylation, with LoD ~0.01–0.08%.

Supports CRC profiling and treatment guidance.

#ddPCR #ColorectalCancer

[Burning Rock @BurningRock2014]

Methylation-based detection for hard-to-detect cancers.

At #AACR2026, we reported CanCatch Surf data across >1,000 in-silico, 280 contrived, and 559 clinical samples, with 84% PDAC / 82% BTC sensitivity at 99% specificity and LoD 0.02%.

Supports early detection and monitoring.

[Burning Rock @BurningRock2014]

One cfDNA sample. Mutation + methylation analysis.

At #AACR2026, Burning Rock presented data on MMcall, showing 98.8% specificity and strong concordance at low VAF (0.5–1%).

Supports MRD monitoring and early detection.

#LiquidBiopsy

[Burning Rock @BurningRock2014]

4 innovations. One goal: advancing precision oncology.

At #AACR2026, Burning Rock presented validation data on MMcall, CanCatch Surf, 25-plex ddPCR and SPIRAL—supporting liquid biopsy. from early detection to treatment guidance and recurrence monitoring.

#LiquidBiopsy

[Burning Rock @BurningRock2014]

⏩1 Week to AACR 2026!

Burning Rock Dx will head to AACR 2026 and present latest liquid biopsy & precision oncology data via oral & poster.

📍Visit us at Booth #4450 to explore more science innovation.

See you in San Diego!

#AACR2026 #LiquidBiopsy #ctDNA #PrecisionOncology

[Burning Rock @BurningRock2014]

Navigate global CDx regulations to empower pharma partnerships.

Join us for:
✅CDx regulatory strategies
✅Multi-regional alignment
✅Real approval & launch cases

📅 Apr 16, 2026
⏰ 8:00 AM PT | 11:00 AM ET | 4:00 PM CET

👉 Register: https://t.co/wqQsF0EsZc

#RegulatoryAffairs

[Burning Rock @BurningRock2014]

Burning Rock (NASDAQ: BNR) reports 2025 Q4 & Full-Year results

FY 2025
✅Total revenue RMB539.6 million (+4.6% YoY)
✅Net loss narrowed 84.0%

Q4
✅First-ever quarterly positive adjusted EBITDA
✅Two consecutive quarters of positive cash flow

Learn More: https://t.co/n85VZ7V9Tk

[Burning Rock @BurningRock2014]

Burning Rock & CTONG Lab scored full marks in 4 international EQA programs by NCCL, CAP & EMQN!

👉Solid/ hereditary cancers, accurate NGS, global-standard English reports.

323 EQA passes + CAP/CLIA/ISO15189: quality powers precision oncology.

Learn More:https://t.co/I7sAjiiQkD

[Burning Rock @BurningRock2014]

Burning Rock Dx’s OncoScreen® BCMatch—China’s first breast cancer NGS CDx —has entered CMDE Priority Review!

Its Capivasertib CDx module has already approved and reimbursed in Japan, accelerating our "One Assay, Global Partnership" strategy.

Learn More：https://t.co/xGPuhcqj3B

[Burning Rock @BurningRock2014]

Burning Rock’s intelligent lab one-stop solution: comprehensive IVD assays, 4-5 day NGS turnaround & user-friendly workflow!

Powers molecular diagnostics/research with reliable results, global access & operational confidence.

#PrecisionOncology #MolecularDiagnostics

[Burning Rock @BurningRock2014]

Burning Rock’s ultra-sensitive liquid biopsy tech ELSA-seq has earned a U.S. patent. This strengthens our international IP protection and advances our mission to deliver high-impact cancer care solutions worldwide.

Learn More:
https://t.co/1GpTBOf8JF

#Patent #LiquidBiopsy

[Burning Rock @BurningRock2014]

Innovation Alert! PRECARE Study (Annals of Surgery) transforms CRC post-op care: CanCatch® personalized ctDNA-MRD testing at D7 matches D30 recurrence prediction—enabling early risk stratification & tailored treatment!

Learn More:
https://t.co/xn7fBh96t0

#ctDNA_MRD

[Labroots @Labroots]

Gain expert insights into the essential components of lab accreditation and quality management at our Dec 9 webinar! Learn how your lab can align with international quality standards. Register: https://t.co/jUnCebqdlr
@BurningRock2014